Nat Rev Neurosci 15:367378 Son JW, Kim S (2020) Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Full story via BioPharma Dive: #EliLilly #Orforglipron #GLP1 #ObesityTreatment #MetabolicDisease #BiopharmaInnovation #ClinicalTrials #FDA #DrugDevelopment #LifeSciences To view or add a comment, sign in FDA approves globally first obesity pill FDA approves Novo Nordisks first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence
This "pulse and sustain" approach more closely mimics your body's natural patterns of hormone secretion
In receptor-driven systems, researchers can often connect ligand binding, receptor activation, downstream signaling, and biological outcome in a relatively linear sequence
It's long been thought that Mounjaro leads to more significant weight loss outcomes than Wegovy but with recent research, that is changing
Before you assume Reta doesn't work or double your dose in frustration, take a breath